Phathom Pharmaceuticals Appoints New Chief Financial Officer

Phathom Pharmaceuticals ( (PHAT) ) has provided an announcement.

On October 6, 2025, Phathom Pharmaceuticals appointed Sanjeev Narula as Chief Financial and Business Officer, succeeding Robert Breedlove as the principal financial officer. Mr. Narula’s extensive experience includes roles at Intra-Cellular Therapies, Viatris Inc., and Pfizer, bringing significant financial leadership to Phathom. His appointment is accompanied by a comprehensive employment agreement that outlines his compensation, severance benefits, and stock options, potentially impacting the company’s strategic financial management and stakeholder interests.

The most recent analyst rating on (PHAT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.

Spark’s Take on PHAT Stock

According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.

Phathom Pharmaceuticals’ overall stock score is primarily influenced by its financial instability, despite strong technical indicators and positive earnings call guidance. The company’s strategic initiatives and FDA exclusivity are promising, but financial challenges remain a significant concern.

To see Spark’s full report on PHAT stock, click here.

More about Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing novel treatments for gastrointestinal diseases.

Average Trading Volume: 1,101,676

Technical Sentiment Signal: Buy

Current Market Cap: $866.2M

Find detailed analytics on PHAT stock on TipRanks’ Stock Analysis page.